Who is sponsoring NCT03966040?

NCT03966040 is sponsored by Jiangsu Province Centers for Disease Control and Prevention.

What drugs are being tested in NCT03966040?

Interventions in NCT03966040: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14.

What condition does NCT03966040 study?

NCT03966040 studies Staphylococcus Aureus Infection.

Is NCT03966040 still recruiting?

NCT03966040 is currently completed. Last updated 30 March 2021.

Last reviewed 2021-03-30 · How we verify

NCT03966040

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Completed Phase 1 Last updated 30 March 2021

What this trial tests

Phase 1 trial testing Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7 in Staphylococcus Aureus Infection in 144 participants. Completed in 16 May 2020.

Timeline

16 May 2019

Primary endpoint
16 December 2019

16 May 2020

Quick facts

Lead sponsor	Jiangsu Province Centers for Disease Control and Prevention
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	144
Start date	16 May 2019
Primary completion	16 December 2019
Estimated completion	16 May 2020
Sites	1 location across China

Drugs / interventions tested

Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7 — full drug profile →
Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7 — full drug profile →
Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7 — full drug profile →
Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14 — full drug profile →

Conditions studied

Staphylococcus Aureus Infection — all drugs for Staphylococcus Aureus Infection →

Sponsor

Jiangsu Province Centers for Disease Control and Prevention — full company profile →

Who can join

Adults 18 to 70, any sex, with Staphylococcus Aureus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, open-label phase1b clinical trial. The study will evaluate the safety and immunogenicity of an experimental recombinant staphylococcus aureus vaccine with different immunization schedules in healthy adults aged 18-70 years, including day 0-3-7, day 0/0-3-7, day 0/0-7 and day 0/0-7-14.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies.
Clegg J, Soldaini E, McLoughlin RM, Rittenhouse S, et al · · 2021 · cited 118× · PMID 34305945 · DOI 10.3389/fimmu.2021.705360
Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials.
Zhu FC, Zeng H, Li JX, Wang B, et al · · 2022 · cited 19× · PMID 35473663 · DOI 10.1016/j.vaccine.2022.04.034
mRNA-based platform for preventing and treating Staphylococcus aureus by targeted staphylococcal enterotoxin B.
Luo F, Xu C, Zhang C, Tan A, et al · · 2024 · cited 13× · PMID 39640268 · DOI 10.3389/fimmu.2024.1490044
Identification and application of a neutralizing epitope within alpha-hemolysin using human serum antibodies elicited by vaccination.
Wei J, Cheng X, Zhang Y, Gao C, et al · · 2021 · cited 6× · PMID 33873093 · DOI 10.1016/j.molimm.2021.03.028
Identification of cross-reactive vaccine antigen candidates in Gram-positive ESKAPE pathogens through subtractive proteome analysis using opsonic sera.
Sadones O, Kramarska E, Sainz-Mejías M, Berisio R, et al · · 2025 · cited 3× · PMID 40138269 · DOI 10.1371/journal.pone.0319933
Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.
Hetta HF, Khalaf FR, Kotb AA, Alatawi MN, et al · · 2025 · cited 1× · PMID 41599011 · DOI 10.3390/pathogens15010028
A promising Staphylococcus aureus vaccine adjuvant candidate to overcome Staphylococcal infection based on innate immunity.
Mao X, Söderhäll T, Choi GS, Kang JH, et al · · 2025 · cited 1× · PMID 40741061 · DOI 10.7774/cevr.2025.14.e27
Potent human antibodies against SpA5 identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells.
Wang W, Li X, Ou Y, Zhou J, et al · · 2025 · cited 1× · PMID 39834865 · DOI 10.1016/j.isci.2024.111627

Verify or expand the search:

Other recruiting trials for Staphylococcus Aureus Infection

Currently open trials in the same condition.

NCT05899140 — Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial · Phase 4 · recruiting
NCT05117398 — Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus · Phase 3 · recruiting
NCT04210505 — Nasal Decolonization of Dialysis Patients Noses · Phase 4 · active not recruiting

Other Jiangsu Province Centers for Disease Control and Prevention trials

Trials by the same sponsor.

NCT07530679 — Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vacc · NA · not yet recruiting
NCT07232745 — Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine · Phase 4 · active not recruiting
NCT06609811 — The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuat · Phase 4 · completed
NCT07035054 — Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · Phase 2 · completed
NCT07025876 — PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03966040 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Centers for Disease Control and Prevention
Last refreshed: 30 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing